Biomarker ID | 1409 |
PMID | 24740842 |
Year | 2014 |
Biomarker | MIR605 [SNP: rs2043556: GG vs. AA/AG] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: Univariate: Cohort 1: [1.97 (95% CI: 1.14–3.40)]; Cohort 1+2: [1.70 (95% CI: 1.07–2.71)]HR: Multivariate: Cohort 1: [2.55 (95% CI: 1.34–4.84)]; Cohort 1+2: [1.96 (95% CI: 1.16–3.30)] |
Effect on Pathways | Pathways include: phosphorylation; dendritic spine; actin filament organization; formation of primary germ layer; germ cell migration |
Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | two independent cohorts composed of 320 Asian and 526 Caucasian men with pathologically organ-confined prostate cancer were selected |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | Univariate: Cohort 1: p= 0.02 Cohort 1+2: p=0.03;Multivariate: Cohort 1:p = 0.004 Cohort 1+2: p=0.01 |
Method Used | MALDI-TOF |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |